Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACETAMINOPHEN AND IBUPROFEN vs AMIKACIN SULFATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Acetaminophen is a centrally acting analgesic and antipyretic whose exact mechanism is not fully understood, but is thought to involve inhibition of cyclooxygenase (COX) in the brain and modulation of cannabinoid receptors. Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that non-selectively inhibits COX-1 and COX-2, reducing prostaglandin synthesis.
Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting protein synthesis. Also disrupts bacterial cell membrane integrity.
Temporary relief of minor aches and pains,Reduction of fever,Off-label: Management of osteoarthritis pain, headache, dysmenorrhea
FDA-approved: Treatment of serious gram-negative bacterial infections (e.g., Pseudomonas aeruginosa, Escherichia coli, Klebsiella, Enterobacter, Serratia, Proteus) when other antibiotics are ineffective or contraindicated.,Off-label: Used in combination for enterococcal endocarditis, mycobacterial infections (e.g., tuberculosis), and severe neonatal sepsis.
Oral: Acetaminophen 325 mg and ibuprofen 200 mg, 1-2 tablets every 6 hours as needed, not exceeding 6 tablets/24 hours.
15 mg/kg/day IV or IM divided every 8-12 hours; typical adult dose 500 mg IV/IM every 12 hours or 7.5 mg/kg every 12 hours.
Acetaminophen: 2-3 hours (normal hepatic function). Ibuprofen: 2-4 hours (immediate-release); prolonged in overdose or hepatic impairment.
Terminal: 2-3 hours (normal renal function); prolonged to 30-50 hours in anuria; neonates 4-8 hours.
Acetaminophen is primarily metabolized via glucuronidation and sulfation; a minor pathway via CYP2E1 produces a toxic metabolite, NAPQI. Ibuprofen is metabolized primarily by CYP2C9 and to a lesser extent by CYP2C8.
Amikacin is not significantly metabolized; it is excreted unchanged primarily by glomerular filtration. Minimal hepatic metabolism.
Acetaminophen: renal excretion of metabolites (glucuronide 55%, sulfate 30%, cysteine/mercapturate <10%); <5% unchanged. Ibuprofen: renal excretion of metabolites (conjugates) 90%; <10% unchanged; minor biliary/fecal.
Renal: >90% unchanged via glomerular filtration. Biliary/fecal: <1%.
Acetaminophen: 10-25% (albumin). Ibuprofen: >99% (albumin).
0-11% (low binding to albumin).
Acetaminophen: 0.9 L/kg; Ibuprofen: 0.15 L/kg (highly protein-bound, low Vd).
0.25-0.4 L/kg; approximates extracellular fluid volume; increased in edema, decreased in dehydration.
Acetaminophen: 75-85% oral. Ibuprofen: 80-100% oral.
IM: nearly 100% (rapid and complete).
GFR 30-59: Caution, use lowest effective dose; GFR <30: Contraindicated due to ibuprofen component.
Cr Cl 20-50 m L/min: 7.5 mg/kg every 24 hours; Cr Cl 10-20 m L/min: 7.5 mg/kg every 48 hours; Cr Cl <10 m L/min: 7.5 mg/kg every 72-96 hours; hemodialysis: 7.5 mg/kg post-dialysis with monitoring.
Child-Pugh A: No adjustment; Child-Pugh B: Caution, reduce acetaminophen dose; Child-Pugh C: Contraindicated.
No dose adjustment required for hepatic impairment; monitor drug levels if severe dysfunction.
Weight-based: 10-15 mg/kg acetaminophen + 5-10 mg/kg ibuprofen per dose, every 6-8 hours, max 4 doses/day.
Neonates <7 days: 15-20 mg/kg IV every 24-48 hours; neonates 7-28 days: 15 mg/kg every 24 hours; infants/children: 15-22.5 mg/kg/day divided every 8-12 hours; maximum 1.5 g/day.
Use lowest effective dose; monitor renal function due to ibuprofen; avoid durations >10 days.
Reduce initial dose based on renal function; usual dose 7.5 mg/kg every 24-48 hours with close monitoring of serum creatinine and drug levels due to age-related decreased GFR.
Acetaminophen may cause severe liver injury, including acute liver failure, at doses exceeding 4,000 mg/day. Ibuprofen: NSAIDs increase risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. Risk increases with duration of use and in patients with cardiovascular risk factors. NSAIDs also increase risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of stomach or intestines.
WARNING: Amikacin can cause neurotoxicity, ototoxicity, and nephrotoxicity. The risk of nephrotoxicity is greater in patients with impaired renal function and those receiving high doses or prolonged therapy. Ototoxicity may be irreversible and can occur even after drug discontinuation. Monitor renal function and drug levels closely.
Acetaminophen: Hepatotoxicity risk with excessive doses, use with caution in hepatic impairment, avoid with alcohol use >3 drinks/day. Ibuprofen: Cardiovascular risk, gastrointestinal bleeding, renal toxicity, hypertension, fluid retention, avoid late pregnancy.
Nephrotoxicity: Risk increased with advanced age, pre-existing renal impairment, concomitant use of other nephrotoxic drugs (e.g., amphotericin B, cyclosporine, NSAIDs).,Ototoxicity: Can cause irreversible bilateral hearing loss, tinnitus, and vestibular damage. Monitor audiometry in patients with risk factors.,Neuromuscular blockade: May exacerbate weakness in patients with neuromuscular disorders (e.g., myasthenia gravis, Parkinsonism). Use with caution during anesthesia or with neuromuscular blocking agents.,Hypersensitivity reactions: Including rash, drug fever, and anaphylaxis.,Superinfection: Prolonged use may lead to overgrowth of nonsusceptible organisms.,Pregnancy: Risk of fetal harm (ototoxicity) if administered during pregnancy.
Acetaminophen: Severe hepatic impairment, allergy to acetaminophen. Ibuprofen: Hypersensitivity to ibuprofen or other NSAIDs, history of asthma/urticaria after NSAIDs, perioperative pain in CABG surgery, severe heart failure, active GI bleeding, late pregnancy.
Hypersensitivity to amikacin, other aminoglycosides, or any component of the formulation.,Preexisting severe renal impairment (unless life-threatening infection and no alternative).,Concurrent use of other nephrotoxic or ototoxic drugs (relative contraindication).,Myasthenia gravis (caution; neuromuscular blocking effect).
Avoid alcohol; take with food or milk to minimize GI irritation. No specific food restrictions.
No significant food interactions. Avoid alcohol as it may increase side effects like dizziness.
First trimester: Acetaminophen is considered low risk; ibuprofen is associated with increased risk of miscarriage and cardiac defects. Second trimester: Acetaminophen is safe; ibuprofen is relatively safe but may cause oligohydramnios. Third trimester: Acetaminophen is safe; ibuprofen is contraindicated due to risk of premature closure of ductus arteriosus, oligohydramnios, and neonatal renal impairment.
Aminoglycosides including amikacin have been associated with fetal ototoxicity and nephrotoxicity when administered during pregnancy. There is a potential for eighth cranial nerve damage and renal impairment in the fetus, particularly during the second and third trimesters. Animal studies have shown evidence of harm, but controlled human studies are lacking. Use only if clearly needed and if safer alternatives are unavailable.
Acetaminophen: low levels in breast milk, M/P ratio ~0.9; considered compatible with breastfeeding. Ibuprofen: minimal excretion, M/P ratio ~0.01; considered compatible. Combination: low risk with recommended doses.
Amikacin is excreted into human milk in low concentrations. The milk-to-plasma ratio is approximately 0.1–0.2. Due to low oral bioavailability from the gastrointestinal tract, systemic effects in the breastfed infant are unlikely. However, caution is advised due to the potential for altered infant gut flora and direct mucosal irritation. Use only if benefits outweigh risks.
No standard adjustment for acetaminophen; ibuprofen dosing unchanged in pregnancy but avoid in third trimester; consider increased clearance of acetaminophen in pregnancy but no dose adjustment recommended.
Pregnancy does not typically require dosing adjustments for amikacin. However, due to increased glomerular filtration rate during pregnancy, levels may be lower; monitor drug concentrations and adjust doses to achieve therapeutic range. Standard dosing based on ideal body weight and renal function should be followed.
Combination product for acute pain; fixed-dose may exceed recommended daily acetaminophen limit if other acetaminophen-containing products are used. Onset of ibuprofen is 30-60 min, acetaminophen 15-30 min; duration 4-6 hours. Caution in renal impairment (ibuprofen) and hepatic impairment (acetaminophen). Avoid in third trimester of pregnancy.
Monitor peak (15-30 mcg/m L) and trough (<5 mcg/m L) levels to avoid nephrotoxicity and ototoxicity. Adjust dose in renal impairment using Cr Cl. Synergy with beta-lactams for Gram-negative infections. Avoid concurrent loop diuretics.
Do not exceed 10 tablets (500 mg acetaminophen/200 mg ibuprofen) per day.,Do not take with other products containing acetaminophen or NSAIDs.,Take with food or milk to reduce stomach upset.,Avoid alcohol while taking this medication.,Seek medical help if pain persists >10 days or fever >3 days.,Store at room temperature, away from moisture.
Take exactly as prescribed; do not skip doses or stop early.,Report any hearing loss, tinnitus, dizziness, or vertigo immediately.,Drink plenty of fluids to maintain hydration, unless contraindicated.,Avoid taking other medications without consulting your doctor, especially water pills or other antibiotics.
"Concomitant use of Ibuprofen (a nonsteroidal anti-inflammatory drug, NSAID) and Methylprednisolone (a systemic corticosteroid) synergistically increases the risk of gastrointestinal (GI) ulceration, bleeding, and perforation due to additive inhibition of prostaglandin synthesis and mucosal protection. Additionally, Ibuprofen may potentiate the immunosuppressive effects of Methylprednisolone, elevating infection risk. This interaction can lead to serious clinical outcomes, including acute GI hemorrhage, perforation, and impaired wound healing."
"The combination of olopatadine, an antihistamine with sedative properties, and ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), may result in additive central nervous system (CNS) depression, leading to increased sedation, dizziness, and impaired psychomotor function. Ibuprofen can inhibit the metabolism of olopatadine via competition for hepatic CYP450 enzymes, potentially elevating olopatadine plasma concentrations and prolonging its systemic effects. Clinically, patients may experience exacerbated drowsiness, reduced alertness, and increased risk of falls or accidents, especially in the elderly or those with compromised hepatic function."
"Ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), can decrease the metabolism of pioglitazone, a thiazolidinedione antidiabetic agent, by inhibiting cytochrome P450 2C8 (CYP2C8) enzyme activity. This inhibition elevates plasma concentrations of pioglitazone, potentially enhancing its hypoglycemic effects and increasing the risk of adverse reactions such as edema, weight gain, and heart failure exacerbation. Clinically, concomitant use may lead to improved glycemic control but also raises concerns for dose-dependent toxicities, necessitating careful monitoring and possible dose adjustment of pioglitazone."
"Amikacin, an aminoglycoside antibiotic, may competitively inhibit the renal tubular secretion and potentially reduce the clearance of masoprocol, a dicarboxylic acid derivative used as a chemotherapeutic agent. This interaction could lead to increased systemic exposure to masoprocol, elevating the risk of dose-dependent toxicities such as severe enteritis, myelosuppression, and hepatotoxicity. Given the narrow therapeutic index of masoprocol, even modest elevations in serum levels may result in clinically significant adverse outcomes."
"Amikacin, an aminoglycoside antibiotic, may competitively inhibit the tubular secretion of mycophenolic acid (MPA) in the renal proximal tubules, leading to reduced renal clearance of MPA. This interaction can result in elevated serum levels of MPA, increasing the risk of dose-related toxicities such as bone marrow suppression (leukopenia, thrombocytopenia), gastrointestinal disturbances, and increased susceptibility to infections. Patients receiving this combination should be closely monitored for signs of MPA toxicity, especially those with pre-existing renal impairment."
"Coadministration of Metocurine, a nondepolarizing neuromuscular blocking agent, with Amikacin, an aminoglycoside antibiotic, may result in enhanced and prolonged neuromuscular blockade. Aminoglycosides can impair acetylcholine release from presynaptic nerve terminals and reduce postsynaptic sensitivity, synergistically augmenting the effects of nondepolarizing agents. This interaction can lead to excessive muscle relaxation, including respiratory muscle paralysis, increasing the risk of apnea and postoperative respiratory depression."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACETAMINOPHEN AND IBUPROFEN vs AMIKACIN SULFATE, answered by our medical review team.
ACETAMINOPHEN AND IBUPROFEN is a NSAID that works by Acetaminophen is a centrally acting analgesic and antipyretic whose exact mechanism is not fully understood, but is thought to involve inhibition of cyclooxygenase (COX) in the brain and modulation of cannabinoid receptors. Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that non-selectively inhibits COX-1 and COX-2, reducing prostaglandin synthesis.. AMIKACIN SULFATE is a Aminoglycoside Antibiotic that works by Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting protein synthesis. Also disrupts bacterial cell membrane integrity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACETAMINOPHEN AND IBUPROFEN and AMIKACIN SULFATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACETAMINOPHEN AND IBUPROFEN is: Oral: Acetaminophen 325 mg and ibuprofen 200 mg, 1-2 tablets every 6 hours as needed, not exceeding 6 tablets/24 hours.. The standard adult dose of AMIKACIN SULFATE is: 15 mg/kg/day IV or IM divided every 8-12 hours; typical adult dose 500 mg IV/IM every 12 hours or 7.5 mg/kg every 12 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining ACETAMINOPHEN AND IBUPROFEN and AMIKACIN SULFATE. Amikacin may decrease the excretion rate of Ibuprofen which could result in a higher serum level. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. ACETAMINOPHEN AND IBUPROFEN is classified as Category D/X. First trimester: Acetaminophen is considered low risk; ibuprofen is associated with increased risk of miscarriage and cardiac defects. Second trimester: Acetaminophen is safe; ibup. AMIKACIN SULFATE is classified as Category D/X. Aminoglycosides including amikacin have been associated with fetal ototoxicity and nephrotoxicity when administered during pregnancy. There is a potential for eighth cranial nerve . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.